Terms: = Head and neck cancer AND IL2, IL-2, 3558, ENSG00000109471, P60568 AND Clinical Outcome
10 results:
1. Distinct effects of asthma and COPD comorbidity on disease expression and outcome in patients with COVID-19.
Song J; Zeng M; Wang H; Qin C; Hou HY; Sun ZY; Xu SP; Wang GP; Guo CL; Deng YK; Wang ZC; Ma J; Pan L; Liao B; Du ZH; Feng QM; Liu Y; Xie JG; Liu Z
Allergy; 2021 Feb; 76(2):483-496. PubMed ID: 32716553
[TBL] [Abstract] [Full Text] [Related]
2. The Effect of Supplementary Omegaven® on the clinical outcome of Patients With Advanced Esophagogastric Adenocarcinoma Receiving Palliative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy: A Phase II clinical trial.
Eltweri AM; Thomas AL; Chung WY; Morgan B; Thompson J; Dennison AR; Bowrey DJ
Anticancer Res; 2019 Feb; 39(2):853-861. PubMed ID: 30711967
[TBL] [Abstract] [Full Text] [Related]
3. Dysfunction of HPV16-specific CD8+ T cells derived from oropharyngeal tumors is related to the expression of Tim-3 but not PD-1.
Hladíková K; Partlová S; Koucký V; Bouček J; Fonteneau JF; Zábrodský M; Tachezy R; Grega M; Špíšek R; Fialová A
Oral Oncol; 2018 Jul; 82():75-82. PubMed ID: 29909905
[TBL] [Abstract] [Full Text] [Related]
4. Prognostic role of serum cytokines in patients with nasopharyngeal carcinoma.
Lu K; Feng X; Deng Q; Sheng L; Liu P; Xu S; Su D
Onkologie; 2012; 35(9):494-8. PubMed ID: 23007146
[TBL] [Abstract] [Full Text] [Related]
5. Covalent linking of proteins and cytokines to suture: enhancing the immune response of head and neck cancer patients.
Shibuya TY; Kim S; Nguyen K; Parikh P; Wadhwa A; Brockardt C; Do J
Laryngoscope; 2003 Nov; 113(11):1870-84. PubMed ID: 14603040
[TBL] [Abstract] [Full Text] [Related]
6. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters.
Mantovani G; Madeddu C; Gramignano G; Lusso MR; Mocci M; Massa E; Ferreli L; Astara G; Macciò A; Serpe R
J Exp Ther Oncol; 2003; 3(4):205-19. PubMed ID: 14567291
[TBL] [Abstract] [Full Text] [Related]
7. Lymphocyte subsets and T(h)1/T(h)2 immune responses in patients with adenocarcinoma of the oesophagus or oesophagogastric junction: relation to pTNM stage and clinical outcome.
van Sandick JW; Boermeester MA; Gisbertz SS; ten Berge IJ; Out TA; van der Pouw Kraan TC; van Lanschot JJ
Cancer Immunol Immunother; 2003 Oct; 52(10):617-24. PubMed ID: 12802519
[TBL] [Abstract] [Full Text] [Related]
8. Locoregional cellular immunotherapy for patients with advanced esophageal cancer.
Toh U; Yamana H; Sueyoshi S; Tanaka T; Niiya F; Katagiri K; Fujita H; Shirozou K; Itoh K
Clin Cancer Res; 2000 Dec; 6(12):4663-73. PubMed ID: 11156218
[TBL] [Abstract] [Full Text] [Related]
9. Alteration of cellular mediated cytotoxicity, T cell receptor zeta (TcR zeta) and apoptosis related gene expression in nasopharyngeal carcinoma (NPC) patients: possible clinical relevance.
Laytragoon-Lewin N; Porwit-MacDonald A; Mellstedt H; Lewin F
Anticancer Res; 2000; 20(2B):1093-100. PubMed ID: 10810402
[TBL] [Abstract] [Full Text] [Related]
10. Soluble interleukin-2 receptor serum level as a predictor of locoregional control and survival for patients with head and neck carcinoma: results of a multivariate prospective study.
Tartour E; Deneux L; Mosseri V; Jaulerry C; Brunin F; Point D; Validire P; Dubray B; Fridman WH; Rodriguez J
Cancer; 1997 Apr; 79(7):1401-8. PubMed ID: 9083163
[TBL] [Abstract] [Full Text] [Related]
